Zura Bio Limited (NASDAQ:ZURA) Director Amit Munshi Buys 159,744 Shares

Zura Bio Limited (NASDAQ:ZURA) Director Amit Munshi acquired 159,744 shares of the company’s stock in a transaction that occurred on Monday, April 22nd. The stock was acquired at an average cost of $3.13 per share, for a total transaction of $499,998.72. Following the acquisition, the director now owns 777,384 shares of the company’s stock, valued at approximately $2,433,211.92. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Zura Bio Stock Down 4.9 %

Shares of NASDAQ:ZURA opened at $3.31 on Thursday. Zura Bio Limited has a 1-year low of $2.00 and a 1-year high of $14.00. The firm’s 50 day simple moving average is $3.21 and its two-hundred day simple moving average is $4.04.

Hedge Funds Weigh In On Zura Bio

Several large investors have recently added to or reduced their stakes in the company. Forefront Analytics LLC lifted its holdings in Zura Bio by 46.8% during the fourth quarter. Forefront Analytics LLC now owns 21,229 shares of the company’s stock valued at $99,000 after purchasing an additional 6,765 shares in the last quarter. Armistice Capital LLC lifted its holdings in Zura Bio by 15.4% during the fourth quarter. Armistice Capital LLC now owns 1,824,000 shares of the company’s stock valued at $8,518,000 after purchasing an additional 244,000 shares in the last quarter. Lynx1 Capital Management LP purchased a new position in shares of Zura Bio in the third quarter worth $65,000. Eisler Capital US LLC purchased a new position in shares of Zura Bio in the third quarter worth $660,000. Finally, Silverarc Capital Management LLC lifted its holdings in shares of Zura Bio by 152.5% in the third quarter. Silverarc Capital Management LLC now owns 404,040 shares of the company’s stock worth $2,667,000 after buying an additional 244,040 shares in the last quarter. Hedge funds and other institutional investors own 61.14% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Oppenheimer reissued an “outperform” rating and issued a $16.00 price objective (down previously from $17.00) on shares of Zura Bio in a report on Monday, April 1st. Four research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Zura Bio presently has a consensus rating of “Buy” and an average price target of $16.40.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.